Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy.
Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.
BMC Infect Dis. 2020 Oct 19;20(1):775. doi: 10.1186/s12879-020-05504-7.
Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel etiologic agent of viral pneumonia. We aimed to compare clinical features of 165 Italian patients with laboratory confirmed or unconfirmed 2019-nCoV pneumonia.
On March 31, 2020, hospitalized patients who presented with fever and/or respiratory symptoms, exposures, and presence of lung imaging features consistent with 2019-nCoV pneumonia were included. Before admission to a hospital ward, patients underwent RT-PCR based SARS-CoV-2 RNA detection in their nasopharyngeal swab samples.
Of 165 patients studied, 119 had positive RT-PCR results and 46 were RT-PCR negative for 2 days or longer (i.e., when the last swab sample was obtained). The median age was 70 years (IQR, 58-78), and 123 (74.6%) of 165 patients had at least one comorbidity. The majority of patients (101/165, 61.2%) had a mild pneumonia, and the remaining patients (64/165, 38.8%) a severe/critical pneumonia. We did not find any substantial difference in symptoms, incubation periods, and radiographic/CT abnormalities as well as in many of the biological abnormalities recorded. However, at multivariable analysis, higher concentrations of hemoglobin (OR, 1.34; 95% CI, 1.11-1.65; P = 0.003) and lower counts of leukocytes (OR, 0.81; 95% CI, 0.72-0.90; P < 0.001) were statistically associated with confirmed COVID-19 diagnosis. While mortality rates were similar, patients with confirmed diagnosis were more likely to receive antivirals (95% vs 19.6%, P < 0.001) and to develop ARDS (63% vs 37%, P = 0.003) than those with unconfirmed COVID-19 diagnosis.
Our findings suggest that unconfirmed 2019-nCoV pneumonia cases may be actually COVID-19 cases and that clinicians should be cautious when managing patients with presentations compatible with COVID-19.
自 2019 年 12 月以来,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)已成为病毒性肺炎的新型病因。我们旨在比较 165 例经实验室确诊或未确诊的 2019 年新型冠状病毒肺炎患者的临床特征。
2020 年 3 月 31 日,纳入出现发热和/或呼吸道症状、暴露史和肺部影像学特征符合 2019 年新型冠状病毒肺炎的住院患者。在收入医院病房之前,对患者的鼻咽拭子样本进行基于 RT-PCR 的 SARS-CoV-2 RNA 检测。
在研究的 165 例患者中,119 例 RT-PCR 结果阳性,46 例 RT-PCR 结果为阴性且持续 2 天或更长时间(即最后一次采集拭子样本)。中位年龄为 70 岁(IQR,58-78),165 例患者中有 123 例(74.6%)至少合并一种合并症。大多数患者(101/165,61.2%)为轻度肺炎,其余患者(64/165,38.8%)为重症/危重症肺炎。我们未发现症状、潜伏期以及影像学/CT 异常以及记录的许多生物学异常有明显差异。然而,多变量分析显示,血红蛋白浓度较高(OR,1.34;95%CI,1.11-1.65;P=0.003)和白细胞计数较低(OR,0.81;95%CI,0.72-0.90;P<0.001)与确诊 COVID-19 诊断相关。虽然死亡率相似,但确诊 COVID-19 患者更有可能接受抗病毒治疗(95% vs 19.6%,P<0.001)和发生急性呼吸窘迫综合征(63% vs 37%,P=0.003)。
我们的研究结果表明,未确诊的 2019 年新型冠状病毒肺炎病例实际上可能为 COVID-19 病例,临床医生在处理临床表现符合 COVID-19 的患者时应谨慎。